1. The Importance of Getting the Dose Right in HF

3. ESC HF Long-Term Registry Use of Pharmacological Therapies

4. ESC HF Long-Term Registry Patients at Target Dose with Recommended Drug Therapies

5. Why Are HF Therapies Not Uptitrated in Eligible Patients?

6. BIOSTAT- HF Uptitration of ACEI/ARB/BB

7. Real-World Titration Patterns of Sacubitril/Valsartan in Germany Purpose and Methods

8. Germany "Real World Data": Sacubitril/Valsartan Use Results

9. TITRATION Study Uptitration of Sacubitril/Valsartan

10. TITRATION Study Uptitration of Sacubitril/Valsartan (cont)

11. Titration of HF Pharmacological Therapies Is There Room for Improvement?

12. Barriers to Uptitration of HF Therapies

13. Uptitration of HF Therapies How Long Does It Take and How Can We Improve?

14. Uptitration of HF Therapies Additional Delays

15. ESC Guidelines Recommendations for Pharmacological Therapies in Chronic HF

16. Uptitration of HF Therapies How Do We Overcome the Delays?

17. Conclusions

18. Abbreviations